Apnimed (APMD) news
Recent news
Apnimed indicated to open at $22 per share, IPO price $16
Apnimed, a pharmaceutical company focused on developing oral treatments for obstructive sleep apnea and related disorders, has drawn attention in the financial markets following reports that its shares opened at $22 apiece in its initial public offering (IPO), exceeding the initial IPO price of $16…
AInvest Wire · Jul 31, 2026APNimed is said to allocate 80% of IPO shares to 10 investors
Apnimed Inc., a clinical-stage biopharmaceutical company focused on developing oral treatments for obstructive sleep apnea, has drawn significant investor interest ahead of its anticipated U.S. initial public offering (IPO). According to recent regulatory filings, the company plans to allocate 80%…
AInvest Wire · Jul 31, 2026Apnimed prices upsized IPO of 12M shares at $16.00 each
AInvest Wire · Jul 31, 2026Apnimed is said to guide IPO pricing to top half of range
AInvest Wire · Jul 30, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.